Autoimmunity Reviews

Papers
(The H4-Index of Autoimmunity Reviews is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Editorial Board236
The rationale for the use of corticosteroids in early severe Guillain-Barré syndrome174
Editorial Board149
“Fibromyalgia syndrome” related to Essure devices136
Leflunomide: A safe and effective alternative in systemic lupus erythematosus134
Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review98
The role of musculoskeletal ultrasound in difficult-to-treat RA: Insights from a systematic literature review90
Issues in autoantibody tests used in the classification criteria for autoimmune rheumatic diseases: the laboratory autoimmunologist's perspective86
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders86
Editorial Board85
Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases84
Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis80
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence74
Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management69
T lymphocyte plasticity in chronic inflammatory diseases: The emerging role of the Ikaros family as a key Th17-Treg switch67
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis67
Susac syndrome: A scoping review66
Conceiving complexity: Biological mechanisms underpinning the lasting effect of pregnancy on multiple sclerosis outcomes61
Endometriosis and autoimmunity61
A call for uniformity in reporting patient level details during description of ophthalmologic major relapse among giant cell arteritis studies. A comment on article by Aussedat M et al. “Epidemiology 61
Editorial Board61
Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature59
The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction59
Can anticoagulation be withdrawn in APS patients after aPL negativization?57
Psychiatric manifestations of autoimmune encephalitis56
Human abdominal aortic aneurysm (AAA): Evidence for an autoimmune antigen-driven disease.56
To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debate55
The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned54
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy54
WITHDRAWN: Global incidence trends of autoimmune diseases from 1990 to 2021 and projections to 2050: A systemic analysis of the global burden of disease study 202152
Homocysteine as a trigger and potential therapeutic target for autoimmune diseases51
Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review50
Worsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA vaccination49
Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered48
Seronegative autoimmune diseases: A challenging diagnosis47
Autoimmunity in vitiligo: Therapeutic implications and opportunities45
Fecal microbiota transplantation in autoimmune diseases – An extensive paper on a pathogenetic therapy44
Autoimmune pre-disease43
Rebalancing redox homeostasis: A pivotal regulator of the cGAS-STING pathway in autoimmune diseases42
Cardiovascular outcome in adult-onset Kawasaki disease41
A descriptive study of IgG4-related disease in children and young adults41
Indian Rheumatology Association guidelines for the management of ANCA associated vasculitis41
1.8068659305573